Clinical Trials List
2022-11-18 - 2027-12-31
Phase I
Not yet recruiting2
Recruiting5
ICD-10C45.9
Mesothelioma, unspecified
ICD-10C79.9
Secondary malignant neoplasm of unspecified site
ICD-10C7A.00
Malignant carcinoid tumor of unspecified site
ICD-10C7A.094
Malignant carcinoid tumor of the foregut NOS
ICD-10C7A.095
Malignant carcinoid tumor of the midgut NOS
ICD-10C7A.096
Malignant carcinoid tumor of the hindgut NOS
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.00
Secondary carcinoid tumors, unspecified site
ICD-10C80.1
Malignant (primary) neoplasm, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.1
Malignant neoplasm of unspecified site (primary) (secondary)
-
Trial Applicant
GILEAD SCIENCES HONG KONG LIMITED
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/12/01
Investigators and Locations
Co-Principal Investigator
- 何宇傑 Division of Radiation Therapy
- 李尚儀 Division of Radiation Therapy
- 林炫聿 Division of Radiation Therapy
- 余萬年 Division of Radiation Therapy
- 王全正 Division of Radiation Therapy
- 楊繕駿 Division of Radiation Therapy
- 林聖皓 Division of Radiation Therapy
- 謝明妤 Division of Radiation Therapy
- 林慶雄 Division of Radiation Therapy
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Mu-Hsin Chang Division of Hematology & Oncology
- Tien-Hua Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HUAI-CHENG HUANG Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Cheng-Lung Hsu Division of Hematology & Oncology
- Hung-Chih Hsu Division of Hematology & Oncology
- 柯皓文 Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- Jen-Shi Chen Division of Hematology & Oncology
- Ping-Chih Hsu Division of Hematology & Oncology
- Wen-Cheng Chang Division of Hematology & Oncology
- Chan-Keng Yang Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
- Hung-Ming Wang Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- 吳教恩 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 曹朝榮 Division of Hematology & Oncology
- 林正耀 Division of Hematology & Oncology
- 陳冠宇 Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 蕭聖諺 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 高婉真 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳國興 Division of Hematology & Oncology
- 黃信端 Division of Hematology & Oncology
- Hsiang-Fong Kao Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- 莊建淮 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
80 participants
-
Global
376 participants
